2023 Webinars
Friday December 1, 2023 | 11:00am-12:00pm ET
“Preclinical Translational Science: The View from Biotech”
Christopher P. Austin, M.D.
CEO-Partner, Flagship Pioneering; CEO, Vesalius Therapeutics
Friday September 22, 2023 | 11:00am-12:00pm ET
"Gene Control Therapeutics"
Jay Bradner, MD
Physician-Scientist and Former President, Novartis Institutes for BioMedical Research
Friday June 2, 2023
"Nav1.7 as a Pain Target and Why Selective Nav1.7 Inhibitors
Have Not Yet Shown Efficacy in Clinical Trials"
David H. Hackos, PhD.
Senior Principal Scientist
Genentech, Inc.
Friday March 10, 2023
"Preclinical Cancer Target Validation: How to Avoid Being Wrong (Even if You Fool Reviewer 3)"
William G. Kaelin, Jr., M.D.
Sidney Farber Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute and Brigham and Women’s Hospital,
Investigator, Howard Hughes Medical Institute
NOTE: The Nature article Common pitfalls in preclinical cancer target validation mentioned by Dr. Kaelin in this seminar is available here.